statements

Oxygenta Pharmaceutical Ltd.

BSE: 524636

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

46.07-0.9 (-1.98%)

23 Oct, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Oxygenta Pharmaceutical Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31	TTM Jun 30
	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	5.39	12.87	20.51	13.72	52.03	60.52	30.99	39.64	109.30	112.98	134.84
Cost of Operating Revenue	6.54	13.29	19.16	18.73	43.49	54.26	37.27	43.63	100.08	104.46	115.90
Gross Profit	-1.15	-0.42	1.34	-5.02	8.53	6.26	-6.28	-3.99	9.21	8.52	18.95
Gross Margin	-21.2	-3.3	6.6	-36.6	16.4	10.3	-20.3	-10.1	8.4	7.5	14.0
Total Operating Expenses	13.90	17.81	23.57	22.58	49.38	60.64	40.16	52.00	123.00	130.67	144.93
Operating Profit	-8.51	-4.94	-3.06	-8.87	2.65	-0.12	-9.17	-12.36	-13.70	-17.69	-10.08
Operating Margin	-157.8	-38.4	-14.9	-64.6	5.1	-0.2	-29.6	-31.2	-12.5	-15.7	-7.5
Financing Income/(Expense) - Net	-0.60	-0.90	-0.75	-1.09	-1.78	-0.92	-1.48	-1.58	-1.94	-4.69	-6.61
Profit before Taxes	-5.72	-4.48	-3.49	-5.94	3.14	-0.49	-11.37	-13.87	-14.35	-22.18	-16.50
Income Taxes	0.09	0.05	-0.24	-0.15	0.21	0.12	0.20	-10.39	-4.05	-4.61	-2.97
Profit after Tax	-5.81	-4.53	-3.25	-5.79	2.93	-0.61	-11.57	-3.48	-10.30	-17.57	-13.53
PAT Margin	-107.8	-35.2	-15.9	-42.2	5.6	-1.0	-37.3	-8.8	-9.4	-15.6	-10.0
EPS - Basic - ex Extraordinary Items	-5.69	-4.44	-3.19	-5.67	2.87	-0.48	-8.15	-1.09	-2.86	-4.75	-3.67
EPS - Diluted - ex Extraordinary Items	-5.69	-4.44	-3.19	-5.67	2.87	-0.48	-8.15	-1.09	-2.86	-4.75	-3.67
EBIT	-8.51	-4.94	-3.06	-8.87	2.65	-0.12	-9.17	-12.36	-13.70	-17.69	-10.08
EBITDA	-7.61	-4.00	-2.04	-7.87	3.84	1.48	-7.12	-9.70	-10.09	-15.37	-7.75
EBITDA Margin	-141.1	-31.1	-10.0	-57.4	7.4	2.4	-23.0	-24.5	-9.2	-13.6	-5.7

Balance Sheet

Abridged

Understanding Balance Sheet

Oxygenta Pharmaceutical Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	C 2022 Mar 31	C 2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	C 2022 Mar 31	C 2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	4.49	4.24	8.80	6.77	15.94	9.56	25.01	24.11	30.94	51.43
Long-Term Investments	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.73	1.48
Property Plant & Equipment - Net	12.88	12.35	11.90	11.42	16.97	20.32	27.91	29.36	37.06	47.60
Total Non-Current Assets	14.48	12.72	12.35	11.85	17.92	21.61	29.26	39.09	51.86	68.25
Total Assets	18.97	16.96	21.16	18.62	33.86	31.18	54.26	63.19	82.80	119.68
Total Current Liabilities	24.44	19.66	18.01	16.97	18.84	8.07	32.90	33.70	85.85	86.10
Long Term Debt	17.99	18.02	20.87	25.44	45.04	51.04	62.25	49.00	21.52	75.29
Total Non-Current Liabilities	21.91	29.21	38.31	42.60	53.05	57.74	67.57	49.62	22.60	76.27
Total Liabilities	46.34	48.87	56.32	59.57	71.88	65.81	100.46	83.31	108.44	162.37
Total Shareholders' Equity	-27.38	-31.91	-35.16	-40.95	-38.02	-34.63	-46.20	-20.12	-25.64	-42.69
Total Equity	-27.38	-31.91	-35.16	-40.95	-38.02	-34.63	-46.20	-20.12	-25.64	-42.69
Total Liabilities & Equity	18.97	16.96	21.16	18.62	33.86	31.18	54.26	63.19	82.80	119.68

Cash Flow

Abridged

Understanding Cash Flow Statement

Oxygenta Pharmaceutical Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
	2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	-4.91	-3.59	-2.24	-4.79	4.13	0.98	-9.52	-11.14	-9.68	-18.69
Working Capital - Increase/(Decrease)	4.84	3.99	-6.29	1.13	-7.51	-3.58	6.40	-3.49	10.58	-13.76
Net CF from Operating Activities	-0.07	0.40	-8.53	-3.66	-3.38	-2.60	-3.12	-14.63	0.89	-32.45
Capital Expenditures - Net	0.91	0.41	0.57	0.52	6.74	4.95	9.64	4.11	11.32	12.86
Net CF from Investing Activities	-0.91	-0.41	-0.57	-0.52	-6.74	-4.95	-9.64	-4.11	-11.34	-14.47
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	4.00	-	29.49	5.45	-
Debt - LT & ST - Issuance/(Retirement) - Total	0.99	0.00	9.10	4.28	10.45	3.26	12.71	-10.76	5.00	47.33
Net Cash Flow from Financing Activities	0.99	0.00	9.10	4.28	10.45	7.26	12.71	18.73	10.45	47.33
Free Cash Flow to Equity	0.01	-0.01	0.01	0.10	0.33	-4.29	-0.05	-29.49	-5.43	2.03
Free Operating CF net dividend	-0.98	-0.01	-9.10	-4.18	-10.12	-7.55	-12.76	-18.73	-10.50	-45.31
Free Operating CF	-0.98	-0.01	-9.10	-4.18	-10.12	-7.55	-12.76	-18.73	-10.50	-45.31

Business Segment Analysis

Oxygenta Pharmaceutical Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Oxygenta Pharmaceutical Ltd.

Regional Segment Analysis

Oxygenta Pharmaceutical Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Oxygenta Pharmaceutical Ltd.

Historical Segment Analysis

Track how Oxygenta Pharmaceutical Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for Oxygenta Pharmaceutical Ltd.

Frequently Asked Questions

What is the revenue of Oxygenta Pharmaceutical Ltd.?

The latest trailing twelve month revenue of Oxygenta Pharmaceutical Ltd. is ₹ 134.84 Cr, reflecting a 1-year growth of 20.60% and a 3-year CAGR of 66.99%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Oxygenta Pharmaceutical Ltd.?

The latest trailing twelve month net profit (PAT) of Oxygenta Pharmaceutical Ltd. is ₹ -13.58 Cr, with a 3-year earnings CAGR of 24.73%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Oxygenta Pharmaceutical Ltd.?

The trailing twelve month EBITDA of Oxygenta Pharmaceutical Ltd. is approximately ₹ -10.08 Cr (based on an operating margin of -7.48%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Oxygenta Pharmaceutical Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Oxygenta Pharmaceutical Ltd. is -3.67. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Oxygenta Pharmaceutical Ltd.?

The debt-to-equity ratio of Oxygenta Pharmaceutical Ltd. stands at -. The interest coverage ratio is -1.53x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Oxygenta Pharmaceutical Ltd.?

The book value per share of Oxygenta Pharmaceutical Ltd. is available in the Balance Sheet section of the Statements tab.

What is the cash flow from operations of Oxygenta Pharmaceutical Ltd.?

The trailing twelve month operating cash flow of Oxygenta Pharmaceutical Ltd. is ₹ -32.45 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Oxygenta Pharmaceutical Ltd. report consolidated or standalone financials?

Oxygenta Pharmaceutical Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.